<DOC>
	<DOCNO>NCT00610675</DOCNO>
	<brief_summary>This trial 52-week , open-label extension trial investigate safety explore efficacy Org 50081 ( Esmirtazapine ) participant complete Protocol 176001 ( P05706 ) ( NCT00482612 ) 176002 ( P05707 ) ( NCT00506389 ) . Participants complete Protocol P05706 P05707 , willing continue treatment Esmirtazapine , participate Protocol 176004 ( P05708 ) signing informed consent .</brief_summary>
	<brief_title>Fifty Two Week Extension Trial Org 50081 ( Esmirtazapine ) Treatment Insomnia ( P05708 )</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<criteria>sign write informed consent scope nature investigation explain , trialrelated evaluation ; complete Protocol P05706 P05707 ; Have safety efficacy assessment conduct per protocol P05706 P05707 . clinically relevant electrocardiogram ( ECG ) abnormality judge investigator ; clinically relevant abnormal laboratory value judge investigator ; adverse event deem relevant exclusion Protocol P05708 judge investigator , significantly non compliant protocol criterion procedure Protocol P05706 P05707 , judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Fifty two week</keyword>
	<keyword>Open label</keyword>
	<keyword>extension</keyword>
</DOC>